Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R DeMars

Showing results (121-130 of 125) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 125 results.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 26, 2014
Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II studyJonathan S Berek, Robert P Edwards, Lynn P Parker, et al.
Nature Medicine|November 5, 1999
Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and NefD T Evans, D H O'Connor, P Jing, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 6, 2025
First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose EscalationCapucine Baldini, Loic Verlingue, Vincent Goldschmidt, et al.
Gynecologic Oncology|September 29, 2016
Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancerJonathan Oh, Minal Barve, Carolyn M Matthews, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 26, 2012
A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriersYuan C Ding, Lesley McGuffog, Sue Healey, et al.
Pageof 13

Showing results (121-130 of 125) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 125 results.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 26, 2014
Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II studyJonathan S Berek, Robert P Edwards, Lynn P Parker, et al.
Nature Medicine|November 5, 1999
Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and NefD T Evans, D H O'Connor, P Jing, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 6, 2025
First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose EscalationCapucine Baldini, Loic Verlingue, Vincent Goldschmidt, et al.
Gynecologic Oncology|September 29, 2016
Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancerJonathan Oh, Minal Barve, Carolyn M Matthews, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 26, 2012
A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriersYuan C Ding, Lesley McGuffog, Sue Healey, et al.
Pageof 13